Core Viewpoint - Harbin Yuyantang Traditional Chinese Medicine Clinic Group Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange, aiming to leverage its innovative "full lifecycle diagnosis and treatment model" to enhance patient care and capitalize on the growing demand for traditional Chinese medicine services in China [1][7]. Group 1: Business Model and Services - The company integrates offline licensed medical institutions with a dedicated online platform, creating a comprehensive service system that includes "offline initial diagnosis and online follow-up" [1][2]. - Yuyantang's "full lifecycle diagnosis and treatment model" covers the stages of "preventive care, disease management, treatment, and recovery," providing personalized health management solutions through modern TCM assessment tools and big data analysis [2][3]. - The company has established a network of 48 self-operated licensed medical institutions in northern China, utilizing a unified cloud-based medical information system for digital management [3]. Group 2: Product Offerings - Yuyantang adheres to the "one person, one prescription" principle, offering various personalized TCM formulations, including decoctions, pills, powders, and ointments, which enhance patient compliance and serve as key components in chronic disease management [4]. - The company has proprietary non-heritage ointments and several self-developed hospital formulations that are continuously refined based on clinical experience, forming a standardized and clinically validated foundation for its services [4]. Group 3: Talent and Team Structure - The company employs 292 full-time medical professionals, ensuring stable and continuous service quality, while its research committee consists of 98 experts, driving innovation and maintaining high standards in patient care [5]. Group 4: Supply Chain and Production Strategy - Yuyantang's core strategy includes building a dedicated facility for producing TCM raw materials, which enhances supply chain security and quality control from raw materials to final products [6]. - The company aims to expand its regional presence in provinces such as Shandong, Hebei, Henan, and Tianjin, while digitally transforming its production facilities to ensure quality assurance [6]. Group 5: Market Opportunities - The traditional Chinese medicine service market is experiencing systemic growth opportunities due to the "Healthy China 2030" initiative and various TCM revitalization policies, aligning with the increasing demand for long-term health management [7]. - Yuyantang's innovative service model and integrated operational ecosystem position it well for accelerated growth through its upcoming public listing, reflecting a shift in the private TCM sector towards standardized and sustainable high-quality development [7].